
Sign up to save your podcasts
Or
Which patients with IDH-mutant glioma should receive an isocitrate dehydrogenase (IDH) inhibitor? A top neurosurgeon weighs in.
Credit available for this activity expires: 6/9/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002598?ecd=bdc_podcast_libsyn_mscpedu
4.3
2323 ratings
Which patients with IDH-mutant glioma should receive an isocitrate dehydrogenase (IDH) inhibitor? A top neurosurgeon weighs in.
Credit available for this activity expires: 6/9/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002598?ecd=bdc_podcast_libsyn_mscpedu
13 Listeners
325 Listeners
108 Listeners
161 Listeners
864 Listeners
493 Listeners
705 Listeners
20 Listeners
280 Listeners
253 Listeners
3,332 Listeners
137 Listeners
1,095 Listeners
7,928 Listeners
185 Listeners
62 Listeners
8 Listeners
427 Listeners
317 Listeners